Cargando…
Impact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial
BACKGROUND: This study describes the effect of TG4010 vaccine on Health related Quality of Life (HRQOL) in patients with stage IIIb and IV non–small-cell lung cancer (NSCLC). METHODS: 148 patients with advanced NSCLC expressing MUC1 were randomly assigned to receive TG4010 plus chemotherapy or chemo...
Autores principales: | Rotonda, Christine, Anota, Amélie, Mercier, Mariette, Bastien, Bérangère, Lacoste, Gisèle, Limacher, Jean-Marc, Quoix, Elisabeth, Bonnetain, Franck |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514809/ https://www.ncbi.nlm.nih.gov/pubmed/26207902 http://dx.doi.org/10.1371/journal.pone.0132568 |
Ejemplares similares
-
TG4010: A therapeutic vaccine against MUC1 expressing tumors
por: Limacher, Jean-Marc, et al.
Publicado: (2012) -
TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study
por: Quoix, Elisabeth, et al.
Publicado: (2014) -
TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial
por: Nemunaitis, John, et al.
Publicado: (2015) -
Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC
por: Tosch, Caroline, et al.
Publicado: (2017) -
Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical review
por: Fiteni, Frédéric, et al.
Publicado: (2016)